Archive


Category: alpelisib

  • EMA starts review of Novartis’ latecomer PD-1 drug tislelizumab

    The EU regulator has started a review of Novartis’ PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the drug due in July. Novartis said the EMA is assessing the cancer immunotherapy as a first-line treatment alongside chemotherapy for squamous or non-squamous NSCLC and […]